Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF
Adult
Biomarkers, Tumor
/ genetics
DNA
/ genetics
DNA Methylation
/ genetics
Female
Humans
Male
Monocarboxylic Acid Transporters
/ genetics
Mutation
/ genetics
Promoter Regions, Genetic
/ genetics
Proto-Oncogene Mas
Proto-Oncogene Proteins B-raf
/ genetics
Thyroid Cancer, Papillary
/ genetics
Thyroid Neoplasms
/ genetics
Thyroid Nodule
/ genetics
Tumor Suppressor Proteins
/ genetics
DNA methylation
RASSF1 protein
SLC5A8 protein
biomarker
circulating tumor DNA
human
mutation
papillary
proto-oncogene proteins B-raf
thyroid cancer
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
29
05
2019
accepted:
13
01
2020
pubmed:
6
2
2020
medline:
9
3
2021
entrez:
5
2
2020
Statut:
ppublish
Résumé
Circulating cell-free DNA (cfDNA) has been considered as a diagnostic source to track genetic and epigenetic alterations in cancer. We aimed to study mutation in addition to the methylation status in the promoter regions of RASSF1 and SLC5A8 genes in tissues and circulating free DNA samples of patients affected with papillary thyroid carcinoma (PTC) and thyroid nodules as controls. BRAF
Substances chimiques
Biomarkers, Tumor
0
MAS1 protein, human
0
Monocarboxylic Acid Transporters
0
Proto-Oncogene Mas
0
RASSF1 protein, human
0
SLC5A8 protein, human
0
Tumor Suppressor Proteins
0
DNA
9007-49-2
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6954-6968Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Alimoghaddam, K., Shariftabrizi, A., Tavangar, M., Sanaat, Z., Rostami, S., Jahani, M., & Ghavamzadeh, A. (2006). Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia. Leukemia & Lymphoma, 47(1), 81-88.
Amato, E., Barbi, S., Fassan, M., Luchini, C., Vicentini, C., Brunelli, M., … Malpeli, G. (2016). RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: Correlation of expression, chromosomal status and epigenetic changes. BMC Cancer, 16(1), 11.
Azizi, M., Teimoori-Toolabi, L., Arzanani, M. K., Azadmanesh, K., Fard-Esfahani, P., & Zeinali, S. (2014). MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biology & Therapy, 15(4), 419-427.
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., … Alani, R. M. (2014). Detection of circulating tumor DNA in early-and late-stage human malignancies. Science Translational Medicine, 6(224), 224ra24.
Bond, C. E., Liu, C., Kawamata, F., McKeone, D. M., Fernando, W., Jamieson, S., … Whitehall, V. L. J. (2018). Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasia. Epigenetics, 13(1), 40-48. https://doi.org/10.1080/15592294.2017.1411446
Brigliadori, G., Foca, F., Dall'Agata, M., Rengucci, C., Melegari, E., Cerasoli, S., … Faedi, M. (2016). Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. Journal of Neuro-Oncology, 128(2), 333-339.
Chan, A. K., Chiu, R. W., & Lo, Y. D. (2003). Cell-free nucleic acids in plasma, serum and urine: A new tool in molecular diagnosis. Annals of Clinical Biochemistry, 40(2), 122-130.
Chuang, T. C., Chuang, A. Y., Poeta, L., Koch, W. M., Califano, J. A., & Tufano, R. P. (2010). Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head & Neck, 32(2), 229-234.
Ciampi, R., & Nikiforov, Y. E. (2007). RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology, 148(3), 936-941.
Condello, V., Macerola, E., Ugolini, C., De Napoli, L., Romei, C., Materazzi, G., … Basolo, F. (2018). Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma. Head & Neck, 40(8), 1752-1758.
Coyle, K. M., Boudreau, J. E., & Marcato, P. (2017). Genetic mutations and epigenetic modifications: Driving cancer and informing precision medicine. BioMed Research International, 2017, 9620870. https://doi.org/10.1155/2017/9620870
Czarniecka, A., Oczko-Wojciechowska, M., & Barczyński, M. (2016). BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surgery, 5(5), 495-505. https://doi.org/10.21037/gs.2016.09.09
da Costa Prando, É., Cavalli, L. R., & Rainho, C. (2011). Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines. Epigenetics, 6(12), 1413-1424.
Dai, G., Levy, O., & Carrasco, N. (1996). Cloning and characterization of the thyroid iodide transporter. Nature, 379(6564), 458-460.
DeLellis, R. A. (2006). Pathology and genetics of thyroid carcinoma. Journal of Surgical Oncology, 94(8), 662-669.
Donninger, H., Vos, M. D., & Clark, G. J. (2007). The RASSF1A tumor suppressor. Journal of Cell Science, 120(18), 3163-3172.
Elangovan, S., Pathania, R., Ramachandran, S., Ananth, S., Padia, R. N., Srinivas, S. R., … Boettger, T. (2013). Molecular mechanism of SLC5A8-inactivation in breast cancer. Molecular and cellular biology, MCB, 33, 01702-01712.
Elisei, R., Ugolini, C., Viola, D., Lupi, C., Biagini, A., Giannini, R., … Basolo, F. (2008). BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. The Journal of Clinical Endocrinology & Metabolism, 93(10), 3943-3949.
Fakhr, E., Zare, F., & Teimoori-Toolabi, L. (2016). Precise and efficient siRNA design: A key point in competent gene silencing. Cancer Gene Therapy, 23(4), 73-82.
Fakhruddin, N., Jabbour, M., Novy, M., Tamim, H., Bahmad, H., Farhat, F., … Mahfouz, R. (2017). BRAF and NRAS mutations in papillary thyroid carcinoma and concordance in BRAF mutations between primary and corresponding lymph node metastases. Scientific Reports, 7(1), 4666. https://doi.org/10.1038/s41598-017-04948-3
Galrão, A. L., Camargo, R. Y., Friguglietti, C. U., Moraes, L., Cerutti, J. M., Serrano-Nascimento, C., … Rubio, I. G. S. (2014). Hypermethylation of a new distal sodium/iodide symporter (NIS) enhancer (NDE) is associated with reduced NIS expression in thyroid tumors. The Journal of Clinical Endocrinology & Metabolism, 99(6), E944-E952. https://doi.org/10.1210/jc.2013-1450
Grawenda, A., & O'neill, E. (2015). Clinical utility of RASSF1A methylation in human malignancies. British Journal of Cancer, 113(3), 372-381.
Bunček, M., Griffiths, AJF, Miller, JH, Suzuki, DT, Lewontin, R., & Gelbart, WM (2000). An introduction to genetic analysis. Biologia Plantarum, 45(1), 50.
Haddadi-Nezhad, S., Larijani, B., Tavangar, S. M., & Nouraei, S. M. (2003). Comparison of fine-needle-nonaspiration with fine-needle-aspiration technique in the cytologic studies of thyroid nodules. Endocrine Pathology, 14(4), 369-373.
Haghpanah, V., Shooshtarizadeh, P., Heshmat, R., Larijani, B., & Tavangar, S. M. (2006). Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma. Applied Immunohistochemistry & Molecular Morphology, 14(4), 422-425.
Haghpanah, V., Soliemanpour, B., Heshmat, R., Mosavi-Jarrahi, A., Tavangar, S., Malekzadeh, R., & Larijani, B. (2006). Endocrine cancer in Iran: Based on cancer registry system. Indian Journal of Cancer, 43(2), 80.
Hu, S., Liu, D., Tufano, R. P., Carson, K. A., Rosenbaum, E., Cohen, Y., … Tolaney, S. (2006). Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. International Journal of Cancer, 119(10), 2322-2329.
Huang, Y., Guan, H., Liu, C., Liu, D., Xu, B., Jiang, L., … Chen, M. (2016). Association between RASSF1A promoter methylation and renal cell cancer susceptibility: A meta-analysis. Genetics and Molecular Research, 15(2).
Iwanaga, T., Takebe, K., Kato, I., Karaki, S. -I., & Kuwahara, A. (2006). Cellular expression of monocarboxylate transporters (MCT) in the digestive tract of the mouse, rat, and humans, with special reference to slc5a8. Biomedical Research, 27(5), 243-254.
Kebebew, E., Weng, J., Bauer, J., Ranvier, G., Clark, O. H., Duh, Q.-Y., … Griffin, A. (2007). The prevalence and prognostic value of BRAF mutation in thyroid cancer. Annals of Surgery, 246(3), 466-471.
Khatami, F., Larijani, B., Heshmat, R., Keshtkar, A., Mohammadamoli, M., Teimoori-Toolabi, L., … Tavangar, S. M. (2017). Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer. PLoS One, 12(9):e0184892.
Khatami, F., Larijani, B., & Tavangar, S. M. (2017). Circulating tumor BRAF mutation and personalized thyroid cancer treatment. Asian Pacific Journal of Cancer Prevention, 18(2), 293.
Khatami, F., Larijani, B., & Tavangar, S. M. (2018). The presence of tumor extrachomosomal circular DNA (ecDNA) as a component of liquid biopsy in blood. Medical Hypotheses, 114, 5-7.
Khatami, F., & Tavangar, S. M. (2018a). Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy. Journal of Diabetes & Metabolic Disorders, 17, 1-12.
Khatami, F., & Tavangar, S. M. (2018b). Genetic and epigenetic of medullary thyroid cancer. Iranian Biomedical Journal, 22(3), 142.
Kim, T. Y., Kim, W. B., Rhee, Y. S., Song, J. Y., Kim, J. M., Gong, G., … Hong, S. J. (2006). The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clinical Endocrinology, 65(3), 364-368.
Knol, A. C., Vallée, A., Herbreteau, G., Nguyen, J. M., Varey, E., Gaultier, A., … Brocard, A. (2016). Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline. Experimental Dermatology, 25(10), 783-788.
Kumar, M., Choudhury, Y., Ghosh, S. K., & Mondal, R. (2018). Application and optimization of minimally invasive cell-free DNA techniques in oncogenomics. Tumor Biology, 40(2), 1010428318760342.
Kwak, J. Y., Jeong, J. J., Kang, S. W., Park, S., Choi, J. R., Park, S. J., … Chung, W. Y. (2013). Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas. Head & neck, 35(11), 1630-1633.
Larijani, B., Mohagheghi, M. A., Bastanhagh, M. H., Mosavi-Jarrahi, A. R., Haghpanah, V., Tavangar, S. M., … Khaleghian, N. (2005). Primary thyroid malignancies in Tehran, Iran. Medical Principles and Practice, 14(6), 396-400.
Larijani, B., Shirzad, M., Mohagheghi, M., Haghpanah, V., Mosavi-Jarrahi, A., Tavangar, S., … Baradar-Jalili, R. (2004). Epidemiologic analysis of the Tehran cancer institute data system registry (TCIDSR). Asian Pacific Journal of Cancer Prevention, 5(1), 36-39.
Lee, J. H., Lee, E. S., & Kim, Y. S. (2007). Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid. Cancer, 110(1), 38-46.
Levy, O., & Carrasco, N. (1997). Structure and function of the thyroid iodide transporter and its implications for thyroid disease. Current Opinion in Endocrinology, Diabetes and Obesity, 4(5), 364-370.
Levy, O., De la Vieja, A., & Carrasco, N. (1998). The Na+/I− symporter (NIS): Recent advances. Journal of Bioenergetics and Biomembranes, 30(2), 195-206.
Li, H., Myeroff, L., Smiraglia, D., Romero, M. F., Pretlow, T. P., Kasturi, L., … Issa, J. -P. (2003). SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proceedings of the National Academy of Sciences, 100(14), 8412-8417.
Lim, D. H., & Maher, E. R. (2010). DNA methylation: A form of epigenetic control of gene expression. The Obstetrician & Gynaecologist, 12(1), 37-42.
Lubitz, C. C., Parangi, S., Holm, T. M., Bernasconi, M. J., Schalck, A. P., Suh, H., … Panka, D. J. (2016). Detection of circulating BRAF(V600E) in patients with papillary thyroid carcinoma. The Journal of Molecular Diagnostics: JMD, 18(1), 100-108. https://doi.org/10.1016/j.jmoldx.2015.08.003
Lubitz, C. C., Zhan, T., Gunda, V., Amin, S., Gigliotti, B. J., Fingeret, A. L., … Wirth, L. J. (2018). Circulating BRAFV600E levels correlate with treatment in patients with thyroid carcinoma. Thyroid, 28(3), 328-339.
Lupi, C., Giannini, R., Ugolini, C., Proietti, A., Berti, P., Minuto, M., … Miccoli, P. (2007). Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism, 92(11), 4085-4090.
Lupo, M., Guttler, R., Geck, Z., Tonozzi, T. R., Kammesheidt, A., & Braunstein, G. D. (2018). Is measurement of circulating tumor dna of diagnostic use in patients with thyroid nodules? Endocrine Practice, 24(5), 453-459.
Martin, P. M., Gopal, E., Ananth, S., Zhuang, L., Itagaki, S., Prasad, B. M., … Ganapathy, V. (2006). Identity of SMCT1 (SLC5A8) as a neuron-specific Na+-coupled transporter for active uptake of l-lactate and ketone bodies in the brain. Journal of Neurochemistry, 98(1), 279-288.
Mattos-Arruda, D., & Caldas, C. (2016). Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. Molecular oncology, 10(3), 464-474.
Migdalska-Sek, M., Pastuszak-Lewandoska, D., Czarnecka, K., Nawrot, E., Domanska, D., Brzezinski, J., … Brzezianska, E. (2011). Methylation profile of selected TSGs in non-cancerous thyroid tissue adjacent to primary PTC. Wspólczesna Onkologia, 15(4), 191-197.
Misawa, K., Mochizuki, D., Imai, A., Endo, S., Mima, M., Misawa, Y., … Mineta, H. (2016). Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer. Oncotarget, 7(18), 26087.
Mohammadi-Asl, J., Larijani, B., Khorgami, Z., Tavangar, S., Haghpanah, V., & Mehdipour, P. (2009). Prevalence of BRAFV600E mutation in Iranian patients with papillary thyroid carcinoma: A single-center study. Journal of Applied Sciences, 9(19), 3593-3597.
Mohammadi-Asl, J., Larijani, B., Khorgami, Z., Tavangar, S. M., Haghpanah, V., Kheirollahi, M., & Mehdipour, P. (2011). Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma. Medical Oncology, 28(4), 1123-1128.
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C., Modlin, L. A., … Merritt, R. E. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine, 20(5), 548-554.
Nikiforov, Y., Paul, W., & Thompson, L. (2009). Diagnostic pathology and molecular genetics of the thyroid. Philadelphia, PA: Lippincott Williams & Wilkins.
Nikiforov, Y. E., & Nikiforova, M. N. (2011). Molecular genetics and diagnosis of thyroid cancer. Nature Reviews Endocrinology, 7(10), 569-580.
Niu, H., Yang, J., Yang, K., & Huang, Y. (2017). The relationship between: A meta-analysis of 14 articles and a bioinformatics of 2 databases (Prisma) rassf1a: A meta-analysis of 14 articles and a bioinformatics of 2 databases (Prisma) promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (Prisma). Medicine, 96(46):e8630.
Omidfar, K., Moinfar, Z., Sohi, A. N., Tavangar, S. M., Haghpanah, V., Heshmat, R., … Larijani, B. (2009). Expression of EGFRvIII in thyroid carcinoma: Immunohistochemical study by camel antibodies. Immunological Investigations, 38(2), 165-180.
Pabalan, N., Kunjantarachot, A., Ruangpratheep, C., Jarjanazi, H., Christofolini, D. M., Barbosa, C. P., & Bianco, B. (2017). Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis. Gynecologic Oncology, 146(3), 603-608.
Park, J. Y., Kim, D., Yang, M., Park, H. Y., Lee, S. H., Rincon, M., … Tockman, M. S. (2013). Gene silencing of SLC5A8 identified by genome-wide methylation profiling in lung cancer. Lung Cancer, 79(3), 198-204.
Park, J. Y., Zheng, W., Kim, D., Cheng, J. Q., Kumar, N., Ahmad, N., & Pow-Sang, J. (2007). Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detection and Prevention, 31(5), 359-365.
Perakis, S., & Speicher, M. R. (2017). Emerging concepts in liquid biopsies. BMC Medicine, 15(1), 75.
Ponomaryova, A. A., Rykova, E. Y., Cherdyntseva, N. V., Skvortsova, T. E., Dobrodeev, A. Y., Zav'yalov, A. A., … Laktionov, P. P. (2013). Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer, 81(3), 397-403.
Pupilli, C., Pinzani, P., Salvianti, F., Fibbi, B., Rossi, M., Petrone, L., … Pazzagli, M. (2013). Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism, 98(8), 3359-3365.
Quillien, V., Lavenu, A., Karayan-Tapon, L., Carpentier, C., Labussière, M., Lesimple, T., … Saikali, S. (2012). Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer, 118(17), 4201-4211.
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014). Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Research, 74(11), 2913-2921. https://doi.org/10.1158/0008-5472.can-14-0155
Rodriguez, A.-M., Perron, B., Lacroix, L., Caillou, B., Leblanc, G. R., Schlumberger, M., … Pourcher, T. (2002). Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes. The Journal of Clinical Endocrinology & Metabolism, 87(7), 3500-3503.
Saeki, Y., Abe, M., Kono, F., Nakazato, A., Ishihara, Y., & Abe, H. (2017). DNA methylation analysis of cancer-related genes from cell-free DNA of patients with cancer. Personalized Medicine Universe, 6, 4-11.
Saffar, H., Sanii, S., Emami, B., Heshmat, R., Panah, V. H., Azimi, S., & Tavangar, S. M. (2013). Evaluation of MMP2 and Caspase-3 expression in 107 cases of papillary thyroid carcinoma and its association with prognostic factors. Pathology-Research and Practice, 209(3), 195-199.
Salvi, S., Gurioli, G., De Giorgi, U., Conteduca, V., Tedaldi, G., Calistri, D., & Casadio, V. (2016). Cell-free DNA as a diagnostic marker for cancer: Current insights. OncoTargets and Therapy, 9, 6549-6559. https://doi.org/10.2147/OTT.S100901
Sandulache, V. C., Williams, M. D., Lai, S. Y., Lu, C., William, W. N., Busaidy, N. L., … Cabanillas, M. E. (2017). Real-time genomic characterization utilizing circulating cell-free DNA in patients with anaplastic thyroid carcinoma. Thyroid, 27(1), 81-87.
Sanii, S., Saffar, H., Tabriz, H. M., Qorbani, M., Haghpanah, V., & Tavangar, S. M. (2012). Expression of matrix metalloproteinase-2, but not caspase-3, facilitates distinction between benign and malignant thyroid follicular neoplasms. Asian Pacific Journal of Cancer Prevention, 13(5), 2175-2178.
Schagdarsurengin, U., Gimm, O., Dralle, H., Hoang-Vu, C., & Dammann, R. (2006). CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid, 16(7), 633-642. https://doi.org/10.1089/thy.2006.16.633
Schmutzler, C., & Köhrle, J. (1998). Implications of the molecular characterization of the sodium-iodide symporter (NIS). Experimental and Clinical Endocrinology & Diabetes, 106(S 03), S1-S10.
Sclafani, F., Chau, I., Cunningham, D., Hahne, J. C., Vlachogiannis, G., Eltahir, Z., … Valeri, N. (2018). KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Scientific Reports, 8(1), 1445. https://doi.org/10.1038/s41598-018-19212-5
Shao, C., Dai, W., Li, H., Tang, W., Jia, S., Wu, X., & Luo, Y. (2017). The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics. PLoS One, 12(2):e0171676.
Stephen, J. K., Chen, K. M., Merritt, J., Chitale, D., Divine, G., & Worsham, M. J. (2015). Methylation markers for early detection and differentiation of follicular thyroid cancer subtypes. Cancer and Clinical Oncology, 4(2), 1-12.
Stephen, J. K., Chitale, D., Narra, V., Chen, K. M., Sawhney, R., & Worsham, M. J. (2011). DNA methylation in thyroid tumorigenesis. Cancers, 3(2), 1732-1743.
Stroun, M., Maurice, P., Vasioukhin, V., Lyautey, J., Lederrey, C., Lefort, F., … Anker, P. (2000). The origin and mechanism of circulating DNA. Annals of the New York Academy of Sciences, 906(1), 161-168.
Tavangar, S., Monajemzadeh, M., Larijani, B., & Haghpanah, V. (2007). Immunohistochemical study of oestrogen receptors in 351 human thyroid glands. Singapore Medical Journal, 48(8), 744-747.
Tommasi, S., Dammann, R., Zhang, Z., Wang, Y., Liu, L., Tsark, W. M., … Pfeifer, G. P. (2005). Tumor susceptibility of Rassf1a knockout mice. Cancer Research, 65(1), 92-98.
Tufano, R. P., Teixeira, G. V., Bishop, J., Carson, K. A., & Xing, M. (2012). BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: A systematic review and meta-analysis. Medicine, 91(5), 274-286.
Vos, M. D., Ellis, C. A., Bell, A., Birrer, M. J., & Clark, G. J. (2000). Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. Journal of Biological Chemistry, 275(46), 35669-35672.
Wan, J. C., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., … Rosenfeld, N. (2017). Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nature Reviews Cancer, 17(4), 223-238.
Wen, G., Wang, H., & Zhong, Z. (2018). Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis. Medicine, 97(11):e9971.
Wojdacz, T. K., & Dobrovic, A. (2007). Methylation-sensitive high resolution melting (MS-HRM): A new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Research, 35(6), e41. https://doi.org/10.1093/nar/gkm013
Xie, H., Tubbs, R., & Yang, B. (2015). Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. International Journal of Clinical and Experimental Pathology, 8(1), 636-642.
Xing, M. (2005). BRAF mutation in thyroid cancer. Endocrine-Related Cancer, 12(2), 245-262.
Xing, M. (2013). Molecular pathogenesis and mechanisms of thyroid cancer. Nature Reviews Cancer, 13(3), 184-199.
Xu, H., Zhan, W., & Chen, Z. (2016). Ras-association domain family 1 isoform A (RASSF1A) gene polymorphism rs1989839 is associated with risk and metastatic potential of osteosarcoma in young Chinese individuals: A multi-center, case-control study. Medical Science Monitor, 22, 4529-4535.
Zane, M., Agostini, M., Enzo, M. V., Casal Ide, E., Del Bianco, P., Torresan, F., … Pelizzo, M. R. (2013). Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer. Biomedicine and Pharmacotherapy, 67(8), 723-730. https://doi.org/10.1016/j.biopha.2013.06.007